ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma

Md Kamrul Hasan, Asmaa Nafady, Atsushi Takatori, Satoshi Kishida, Miki Ohira, Yusuke Suenaga, Shamim Hossain, Jesmin Akter, Atsushi Ogura, Yohko Nakamura, Kenji Kadomatsu, Akira Nakagawara

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Human anaplastic lymphoma kinase (ALK) has been identified as an oncogene that is mutated or amplified in NBLs. To obtain a better understanding of the molecular events associated with ALK in the pathogenesis of NBL, it is necessary to clarify how ALK gene contributes to NBL progression. In the present study, we found that ALK expression was significantly high in NBL clinical samples with amplified MYCN (n = 126, P < 0.01) and in developing tumors of MYCN-transgenic mice. Indeed, promoter analysis revealed that ALK is a direct transcriptional target of MYCN. Overexpression and knockdown of ALK demonstrated its function in cell proliferation, migration and invasion. Moreover, treatment with an ALK inhibitor, TAE-684, efficiently suppressed such biological effects in MYCN amplified cells and tumor growth of the xenograft in mice. Our present findings explore the fundamental understanding of ALK in order to develop novel therapeutic tools by targeting ALK for aggressive NBL treatment.

Original languageEnglish
Article number3450
JournalScientific reports
Volume3
DOIs
Publication statusPublished - Dec 20 2013

Fingerprint

Neuroblastoma
Cell Movement
Genes
anaplastic lymphoma kinase
Oncogenes
Heterografts
Transgenic Mice
Neoplasms
Cell Proliferation
Growth

All Science Journal Classification (ASJC) codes

  • General

Cite this

Hasan, M. K., Nafady, A., Takatori, A., Kishida, S., Ohira, M., Suenaga, Y., ... Nakagawara, A. (2013). ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Scientific reports, 3, [3450]. https://doi.org/10.1038/srep03450

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. / Hasan, Md Kamrul; Nafady, Asmaa; Takatori, Atsushi; Kishida, Satoshi; Ohira, Miki; Suenaga, Yusuke; Hossain, Shamim; Akter, Jesmin; Ogura, Atsushi; Nakamura, Yohko; Kadomatsu, Kenji; Nakagawara, Akira.

In: Scientific reports, Vol. 3, 3450, 20.12.2013.

Research output: Contribution to journalArticle

Hasan, MK, Nafady, A, Takatori, A, Kishida, S, Ohira, M, Suenaga, Y, Hossain, S, Akter, J, Ogura, A, Nakamura, Y, Kadomatsu, K & Nakagawara, A 2013, 'ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma', Scientific reports, vol. 3, 3450. https://doi.org/10.1038/srep03450
Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y et al. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Scientific reports. 2013 Dec 20;3. 3450. https://doi.org/10.1038/srep03450
Hasan, Md Kamrul ; Nafady, Asmaa ; Takatori, Atsushi ; Kishida, Satoshi ; Ohira, Miki ; Suenaga, Yusuke ; Hossain, Shamim ; Akter, Jesmin ; Ogura, Atsushi ; Nakamura, Yohko ; Kadomatsu, Kenji ; Nakagawara, Akira. / ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. In: Scientific reports. 2013 ; Vol. 3.
@article{f5051a9bc0b044778cf69120f1e6d3a9,
title = "ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma",
abstract = "Human anaplastic lymphoma kinase (ALK) has been identified as an oncogene that is mutated or amplified in NBLs. To obtain a better understanding of the molecular events associated with ALK in the pathogenesis of NBL, it is necessary to clarify how ALK gene contributes to NBL progression. In the present study, we found that ALK expression was significantly high in NBL clinical samples with amplified MYCN (n = 126, P < 0.01) and in developing tumors of MYCN-transgenic mice. Indeed, promoter analysis revealed that ALK is a direct transcriptional target of MYCN. Overexpression and knockdown of ALK demonstrated its function in cell proliferation, migration and invasion. Moreover, treatment with an ALK inhibitor, TAE-684, efficiently suppressed such biological effects in MYCN amplified cells and tumor growth of the xenograft in mice. Our present findings explore the fundamental understanding of ALK in order to develop novel therapeutic tools by targeting ALK for aggressive NBL treatment.",
author = "Hasan, {Md Kamrul} and Asmaa Nafady and Atsushi Takatori and Satoshi Kishida and Miki Ohira and Yusuke Suenaga and Shamim Hossain and Jesmin Akter and Atsushi Ogura and Yohko Nakamura and Kenji Kadomatsu and Akira Nakagawara",
year = "2013",
month = "12",
day = "20",
doi = "10.1038/srep03450",
language = "English",
volume = "3",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma

AU - Hasan, Md Kamrul

AU - Nafady, Asmaa

AU - Takatori, Atsushi

AU - Kishida, Satoshi

AU - Ohira, Miki

AU - Suenaga, Yusuke

AU - Hossain, Shamim

AU - Akter, Jesmin

AU - Ogura, Atsushi

AU - Nakamura, Yohko

AU - Kadomatsu, Kenji

AU - Nakagawara, Akira

PY - 2013/12/20

Y1 - 2013/12/20

N2 - Human anaplastic lymphoma kinase (ALK) has been identified as an oncogene that is mutated or amplified in NBLs. To obtain a better understanding of the molecular events associated with ALK in the pathogenesis of NBL, it is necessary to clarify how ALK gene contributes to NBL progression. In the present study, we found that ALK expression was significantly high in NBL clinical samples with amplified MYCN (n = 126, P < 0.01) and in developing tumors of MYCN-transgenic mice. Indeed, promoter analysis revealed that ALK is a direct transcriptional target of MYCN. Overexpression and knockdown of ALK demonstrated its function in cell proliferation, migration and invasion. Moreover, treatment with an ALK inhibitor, TAE-684, efficiently suppressed such biological effects in MYCN amplified cells and tumor growth of the xenograft in mice. Our present findings explore the fundamental understanding of ALK in order to develop novel therapeutic tools by targeting ALK for aggressive NBL treatment.

AB - Human anaplastic lymphoma kinase (ALK) has been identified as an oncogene that is mutated or amplified in NBLs. To obtain a better understanding of the molecular events associated with ALK in the pathogenesis of NBL, it is necessary to clarify how ALK gene contributes to NBL progression. In the present study, we found that ALK expression was significantly high in NBL clinical samples with amplified MYCN (n = 126, P < 0.01) and in developing tumors of MYCN-transgenic mice. Indeed, promoter analysis revealed that ALK is a direct transcriptional target of MYCN. Overexpression and knockdown of ALK demonstrated its function in cell proliferation, migration and invasion. Moreover, treatment with an ALK inhibitor, TAE-684, efficiently suppressed such biological effects in MYCN amplified cells and tumor growth of the xenograft in mice. Our present findings explore the fundamental understanding of ALK in order to develop novel therapeutic tools by targeting ALK for aggressive NBL treatment.

UR - http://www.scopus.com/inward/record.url?scp=84890949034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890949034&partnerID=8YFLogxK

U2 - 10.1038/srep03450

DO - 10.1038/srep03450

M3 - Article

C2 - 24356251

AN - SCOPUS:84890949034

VL - 3

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 3450

ER -